|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||70.35 - 72.44|
|52 Week Range||59.60 - 88.87|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||84.03|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sponsors, CROs, and Sites Retain and Easily Access End Of Study Media Necessary to Meet Regulatory Requirements
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Discovery of biomarker evidence in Castleman Disease exemplifies the value of personalized medicine in rare diseases
NEW YORK-- -- Rave Engage Named Top Technology for Sponsors at 14th Annual Scrip Awards Medidata Wins Prestigious Industry Award for Third Consecutive Year Scrip Award Celebrates Innovation and Excellence in Biopharmaceutical Industry Medidata is pleased to announce that Rave Engage was recognized at the 2018 Scrip Awards as the "Best Technological Development in Clinical Trials - Tech Sponsor ...
The United States District Court for the Southern District of New York has rejected Veeva’s motion to dismiss Medidata’s complaint against Veeva for theft of trade secrets, the company announced today. “The Court’s decision allows us to continue with our effort to hold Veeva accountable for its illegal and unethical misappropriation of Medidata’s valuable proprietary information and trade secrets,” said Erik Snider, senior director of corporate communications at Medidata.
NEW YORK-- -- Medidata Rave Omics Machine Learning Identifies New Evidence of Biomarkers in Rare Disease Research by the Castleman Disease Collaborative Network Memorial Sloan Kettering Cancer Center Monitors Newly Diagnosed Myeloma Patients with Medidata ePRO The Castleman Disease Collaborative Network will present results of a large-scale proteomics study of idiopathic multicentric Castleman disease ...
SHYFT Analytics, a Medidata Solutions (MDSO) company, and PAREXEL International, a leading innovator of global biopharmaceutical services, today announced that the companies have entered into a strategic partnership that establishes SHYFT’s technology as an integral part of PAREXEL’s foundation for Real-World Evidence (RWE) generation and outcomes research for biopharmaceutical and medical device clients. The collaboration combines PAREXEL’s innovative scientific and clinical services with SHYFT’s market-leading suite of RWE products to provide insights and outcomes from patient-level data more efficiently to customers worldwide.
NEW YORK-- -- French biopharmaceutical company aims to improve data access, quality, and workflow efficiencies Expansion agreement builds upon success in use of Rave EDC Company developing therapies for rare forms of cancer and orphan diseases Medidata today announced that ERYTECH expanded its use of the Medidata Cloud, the Intelligent Platform for Life Sciences, to streamline clinical trial operations. ...
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CRO accelerates the delivery of life-changing therapies with a single view of data for all clinical trial stakeholders
Medidata (MDSO) is committed to creating a better world for patients. The company spent the past year building a corporate social responsibility program dedicated to STEM education, patient advocacy and global inclusion.
Over 1,000 industry leaders to discuss best practices and the hottest topics in the digital transformation of life sciences
Medidata (MDSO) announced today that it has appointed Dr. Maria Rivas to its Board of Directors. An endocrinologist with extensive experience as a senior leader in the pharmaceutical industry, Dr. Rivas becomes the first woman to serve on the company’s board. “We are thrilled that Maria has joined our board,” said Tarek Sherif, chairman and chief executive officer, Medidata.
Medidata Enables Digital Transformation in Life Sciences with Largest Data Repository, Powered by AI and Advanced Analytics
Medidata today announced that it will release its third quarter 2018 financial results before the market opens on Thursday, October 18, 2018. The company will also hold a conference call at 8 a.m.
NEW YORK, Oct. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Medidata (MDSO) today announced that Decibel Therapeutics is adopting Medidata Cloud, the Intelligent Platform for Life Sciences. The agreement will support the Boston biotech company’s clinical development for hearing loss, tinnitus, and balance disorders.